Phase I clinical and pharmacokinetic study of hexamethylene bisacetamide (NSC 95580) administered as a five-day continuous infusion.
about
Determination of hexamethylene bisacetamide, an antineoplastic compound, in mouse and human plasma by LC-MS/MSPresage of oncolytic virotherapy for oral cancer with herpes simplex virus.Polar/apolar chemical inducers of differentiation of transformed cells: strategies to improve therapeutic potentialStudy of the role of retinoblastoma protein in terminal differentiation of murine erythroleukemia cells.Induced differentiation of erythroleukemia cells by hexamethylene bisacetamide: a model for cytodifferentiation of transformed cells.Inducing differentiation of transformed cells with hybrid polar compounds: a cell cycle-dependent process.Enhancement of the radiosensitivity of two human tumour cell lines by hexamethylene bisacetamide.Targeting HIV latency: pharmacologic strategies toward eradication.Oncolytic herpes viruses, chemotherapeutics, and other cancer drugsPotent cytodifferentiating agents related to hexamethylenebisacetamideHexamethylene bisacetamide leads to reduced helper virus-free HSV-1 amplicon expression titers via suppression of ICP0.Activity of interferon alpha, interleukin 6 and insulin in the regulation of differentiation in A549 alveolar carcinoma cellsContrasting effect of the latency-reversing agents bryostatin-1 and JQ1 on astrocyte-mediated neuroinflammation and brain neutrophil invasion.
P2860
Q33396055-DE28C2A9-3D9A-4925-BE4A-76D34FBFCBE2Q33603748-B5F0D9E4-848D-49AB-99D2-88A3F87D9B68Q34298232-2EE303E5-7F15-41D4-A4AC-4E3846F8E5D9Q34314510-AA938EAC-4936-4148-9666-552B52530BE1Q35032944-34EF4F33-E619-40D8-9C99-37BB14FFF07FQ35844125-BBA2C5E1-10FF-4160-BD89-4000BBE7CFE4Q35981594-5903F0B7-A70C-48C9-A59A-CDB8CCDF3069Q36901950-9806C957-B852-4761-A295-1BAAD13641C0Q37031896-DB2ED722-8D11-4987-88C2-A54D523800DAQ37537900-CA9423FF-193B-4ACD-9B1E-B6C2015F816AQ39601616-9D76861E-3D92-4F7C-90BE-6DB1B0C24729Q41372901-3E5702F3-3C4B-4495-9BE4-1E154A8E0711Q47147442-A9516149-0B5B-43DF-9E6E-61075A5ABDD8
P2860
Phase I clinical and pharmacokinetic study of hexamethylene bisacetamide (NSC 95580) administered as a five-day continuous infusion.
description
1987 nî lūn-bûn
@nan
1987 թուականի Յունուարին հրատարակուած գիտական յօդուած
@hyw
1987 թվականի հունվարին հրատարակված գիտական հոդված
@hy
1987年の論文
@ja
1987年論文
@yue
1987年論文
@zh-hant
1987年論文
@zh-hk
1987年論文
@zh-mo
1987年論文
@zh-tw
1987年论文
@wuu
name
Phase I clinical and pharmacok ...... five-day continuous infusion.
@ast
Phase I clinical and pharmacok ...... five-day continuous infusion.
@en
type
label
Phase I clinical and pharmacok ...... five-day continuous infusion.
@ast
Phase I clinical and pharmacok ...... five-day continuous infusion.
@en
prefLabel
Phase I clinical and pharmacok ...... five-day continuous infusion.
@ast
Phase I clinical and pharmacok ...... five-day continuous infusion.
@en
P2093
P1433
P1476
Phase I clinical and pharmacok ...... a five-day continuous infusion
@en
P2093
P304
P407
P577
1987-01-01T00:00:00Z